PLCXD2-AS1

Across TCGA pan-cancer cohorts, PLCXD2-AS1 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of PLCXD2-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where PLCXD2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PLCXD2-AS1 is over-expressed in tumor, although a few such as THCA and BRCA show the opposite, repressed pattern.

STAD, UCEC, and HNSC are the cancer types where PLCXD2-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLCXD2-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.309	<.001	7	view →
UCEC	All	IV	+0.525	.031	6	view →
HNSC	All	All	+0.122	.002	6	view →
LUAD	All	All	+0.197	.003	4	view →
THCA	Female	All	−0.200	<.001	3	view →
BLCA	Male	III,IV	+0.264	.013	2	view →
LUSC	All	All	+0.145	.002	2	view →
BRCA	All	III,IV	−0.081	.042	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

PLCXD2-AS1–STAD

Open the STAD breakdown →